Meningitis

Inventprise Completes Vaccination of Participants in a Phase 2 Dose Ranging Study of its 25 Valent Pneumococcal Vaccine Candidate

Retrieved on: 
Tuesday, January 2, 2024
Biotechnology, Pharmaceutical, Health, Clinical Trials, PCV, Risk, Death, Pneumonia, Streptococcus, Disease, Ageing, IVT, Vaccination, PATH, Meningitis, Bill, Safety, Sepsis, Vaccine

Biotechnology company Inventprise Inc. today announced the completion of vaccination in their Phase 2 dose ranging study of its 25-valent pneumococcal conjugate vaccine (IVT PCV-25) in young adults.

Key Points: 
  • Biotechnology company Inventprise Inc. today announced the completion of vaccination in their Phase 2 dose ranging study of its 25-valent pneumococcal conjugate vaccine (IVT PCV-25) in young adults.
  • This Phase 2 study is an important step in the efforts to develop an affordable, expanded-coverage pneumococcal conjugate vaccine (PCV).
  • The Inventprise PCV includes 25 serotypes—expanding the potential to prevent several deadly and emerging serotypes not yet addressed by existing PCVs.
  • A Phase 2 study in older adults is also planned to take place in the second half of 2024.

RevBio Receives FDA Approval to Conduct a First-in-Human Clinical Trial for its Regenerative Bone Adhesive for Cranial Flap Fixation

Retrieved on: 
Friday, December 8, 2023
Research, Surgery, Medical Devices, Medical Supplies, FDA, Clinical Trials, Biotechnology, Health, Science, Subdural empyema, Safety, Food, Crystal skull, Risk, Aneurysm, CSF, Clinical trial, Multimedia, Skull, Infection, Osteoblast, MPH, Pain, Intracranial pressure, Cerebrospinal fluid, Meningitis, Architecture, Boston, MD, Brigham, Doctor of Philosophy

This approval was largely predicated on the successful pivotal preclinical and surgeon handling testing conducted by the company.

Key Points: 
  • This approval was largely predicated on the successful pivotal preclinical and surgeon handling testing conducted by the company.
  • As part of the surgical closure process, the cranial flap is secured back into place with plates and screws.
  • The kerf line, however, is typically not sealed, which compromises the ability of the flap to integrate with the surrounding bone.
  • “We are truly excited to move this project into the clinical phase of testing,” said Brian Hess, CEO and Founder of RevBio.

Katalin Karikó and Anne Schuchat Receive 2023 Fries Prize for Improving Health

Retrieved on: 
Sunday, November 12, 2023
DRS, Infant, Pneumonia, Nobel Prize, Cell, Epidemic Intelligence Service, GAVI, Immunization, CDC, Group B streptococcal infection, NCIRD, Doctor of Philosophy, USPHS, University of Szeged, COVID, Organization, Erich Fried Prize, Health, American Public Health Association, RADM, Parent, ARD International Music Competition, Letter, Public, Meningitis, RNA, Therapy, University of Pennsylvania, Anne Schuchat, Infection, APHA, University, RET, SARS, Research, Developmental Biology (journal), Death, Vaccine, Messenger, COVID-19, GBS, Nursing, Management, Pharmaceutical industry, Physiology, Ophthalmology, Medicine, MD

ATLANTA, Nov. 12, 2023 /PRNewswire/ -- Nobel Prize Winner Katalin Karikó, PhD, and former Centers for Disease Control and Prevention (CDC) Principal Deputy Director Anne Schuchat, MD (RADM, USPHS, RET), today received the 2023 Fries Prize for Improving Health.

Key Points: 
  • ATLANTA, Nov. 12, 2023 /PRNewswire/ -- Nobel Prize Winner Katalin Karikó, PhD, and former Centers for Disease Control and Prevention (CDC) Principal Deputy Director Anne Schuchat, MD (RADM, USPHS, RET), today received the 2023 Fries Prize for Improving Health.
  • The Fries Prize for Improving Health award was presented this morning at the American Public Health Association's (APHA) annual meeting, which is taking place in Atlanta.
  • The monetary award for the Fries Prize for Improving Health is $70,000, which will be divided between the recipients.
  • As of 2016, the CDC Foundation manages and administers the Fries Foundation's public health award programs, which include the Fries Prize for Improving Health and the Elizabeth Fries Health Education Award.

BioCina Expands Partnership with GPN Vaccines

Retrieved on: 
Monday, November 6, 2023
CGMP, Escherichia coli, Gamma, GPN, Vaccine, CDMO, Pneumonia, Meningitis, Death, A-DNA, Partnership, Streptococcus pneumoniae, Bacteria, Fungal infection, Streptococcus

ADELAIDE, South Australia, Nov. 6, 2023 /PRNewswire/ -- BioCina Pty Ltd., a global end-to-end biologics contract development and manufacturing organization (CDMO), announced the expansion of their partnership with GPN Vaccines Ltd. GPN Vaccines is a biotechnology company developing a proprietary engineered whole-cell vaccine called Gamma-PN™ against Streptococcus pneumoniae.

Key Points: 
  • ADELAIDE, South Australia, Nov. 6, 2023 /PRNewswire/ -- BioCina Pty Ltd., a global end-to-end biologics contract development and manufacturing organization (CDMO), announced the expansion of their partnership with GPN Vaccines Ltd. GPN Vaccines is a biotechnology company developing a proprietary engineered whole-cell vaccine called Gamma-PN™ against Streptococcus pneumoniae.
  • This bacterium is responsible for causing life-threatening infections such as pneumonia, bacteraemia and meningitis, each year causing up to 2 million deaths worldwide.
  • The BioCina facility in Adelaide, Australia has a rich history of developing and manufacturing recombinant proteins in microbial systems such as E. coli.
  • GPN Vaccines' Chairman & Chief Executive Officer, Professor Tim Hirst said, "We are delighted to be progressing with the next stage of cGMP manufacture of our innovative whole cell pneumococcal vaccine, Gamma-PN™, with BioCina as the CDMO of choice.

Solihull farmer takes on Atlantic row in son's memory

Retrieved on: 
Sunday, October 29, 2023
Always Look on the Bright Side of Life, Meningitis, Nature, Balsall Common, Get Ahead, Ageing, Awareness, Memory, BBC West Midlands, Whaling, Nursing, Facebook, Atlantic Ocean

Solihull farmer takes on Atlantic row in son's memory

Key Points: 
  • Solihull farmer takes on Atlantic row in son's memory
    - Published
    A farmer is preparing to row across the Atlantic ocean in memory of his son who died from meningitis.
  • Rod Adlington, from Balsall Common in Solihull, will be part of a four-man crew taking on the unaided 3,000 mile (4,828km) journey starting from Lanzarote.
  • His son Barney died from the illness 18 years ago, aged three.
  • He said he wants to raise awareness of the illness, and hopes to raise £250,000 for charity.

Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-31 for the Prevention of Invasive Pneumococcal Disease in Adults

Retrieved on: 
Thursday, October 19, 2023
PCV, FDA, Trial of the century, Genetically modified bacteria, IND, Ageing, Food, IPD, Disease, Streptococcus pneumoniae, Regulation of tobacco by the U.S. Food and Drug Administration, Meningitis, Safety, SAN, Investigational New Drug, Vaccine, Pharmaceutical industry

SAN CARLOS, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today that the U.S. Food and Drug Administration (FDA) has cleared the Company’s adult Investigational New Drug (IND) application for VAX-31, a 31-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD). Vaxcyte expects to initiate the VAX-31 Phase 1/2 clinical study in adults in the fourth quarter of this year and announce topline safety, tolerability and immunogenicity results in the second half of 2024.

Key Points: 
  • -- VAX-31 is a 31-Valent Pneumococcal Conjugate Vaccine Designed to Provide Coverage for Approximately 95% of Disease Currently Circulating in the U.S.
  • Adult Population --
    SAN CARLOS, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today that the U.S. Food and Drug Administration (FDA) has cleared the Company’s adult Investigational New Drug (IND) application for VAX-31, a 31-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD).
  • Vaxcyte expects to initiate the VAX-31 Phase 1/2 clinical study in adults in the fourth quarter of this year and announce topline safety, tolerability and immunogenicity results in the second half of 2024.
  • This is important given IPD contributes to high-case fatality rates, antibacterial resistance and meningitis, all of which are particularly concerning in the older adult population.”

Illinois HIV Care Connect’s Health Beyond HIV Campaign Offers Advice to Avoid or Manage Chronic Medical Conditions

Retrieved on: 
Tuesday, September 12, 2023
Diabetes, Hispanic, AIDS, Health, Consumer, Other Health, Pharmaceutical, Other Science, Mental Health, Research, Infectious Diseases, General Health, LGBTQ+, Science, Vaccine, Exercise, Illinois Department of Public Health, Vaccination, Depression, Diet, Chronic kidney disease, HIV, Anxiety, Cardiovascular disease, Cancer, Hepatitis A, Immunity, ART, Woman, Breast, Hepatitis B, Mpox, COVID, Prostate, Person, Bangladesh Technical Education Board, Centers for Disease Control and Prevention, Hepatitis C, Colon, CDC, Public health, Tuberculosis, Risk, Blood, Carbohydrate, HPV, Viral load, CD4, Sodium, Mental health, Meningitis, Pneumonia, Social media

Through website and social media content, the campaign will feature information that can help persons living with HIV to avoid or manage chronic medical conditions, known as co-morbidities.

Key Points: 
  • Through website and social media content, the campaign will feature information that can help persons living with HIV to avoid or manage chronic medical conditions, known as co-morbidities.
  • According to the National Institutes of Health, persons living with HIV are at elevated risk for developing chronic health conditions such as cardiovascular disease, cancer, diabetes mellitus, and chronic kidney disease.
  • “Getting and staying in regular health care can be a challenge for anyone, but it’s especially important for persons living with HIV,” said Michael Maginn, HIV prevention director, Illinois Public Health Association, which manages Illinois HIV Care Connect with funding from the Illinois Department of Public Health.
  • A Health Beyond HIV Quiz offers an easy way to understand how to reduce risks associated with HIV.

Meijer Pharmacists Prepared for Customers' Fall Vaccination Needs

Retrieved on: 
Thursday, September 7, 2023
Vaccine, Vaccination, Hospital, COVID-19, Shingles, Cough, Pharmacist, RSV, Patient, Korea Disease Control and Prevention Agency, Tetanus, Health, FDA, Meningitis, Pneumonia, Pharmacy, Meijer

GRAND RAPIDS, Mich., Sept. 7, 2023 /PRNewswire/ -- Meijer pharmacies are prepared for customers' fall vaccination needs with a full inventory of flu shots ahead of flu season and the first ever FDA-approved Respiratory Syncytial Virus (RSV) vaccine for adults 60 and older.

Key Points: 
  • GRAND RAPIDS, Mich., Sept. 7, 2023 /PRNewswire/ -- Meijer pharmacies are prepared for customers' fall vaccination needs with a full inventory of flu shots ahead of flu season and the first ever FDA-approved Respiratory Syncytial Virus (RSV) vaccine for adults 60 and older.
  • Meijer has ample inventory of it and more than 15 other available vaccinations.
  • "Meijer cares about the communities we serve, and our pharmacists work diligently to help our customers keep their families healthy all year long," said Jackie Morse, Group Vice President of Pharmacy at Meijer.
  • To schedule a vaccine appointment, text "VACCINE" to 75049, visit Clinic.Meijer.com , or call your local Meijer pharmacy.

Is it okay to kiss your pet? The risk of animal-borne diseases is small, but real

Retrieved on: 
Monday, September 4, 2023
Salmonellosis, Infection, Human, Food, Rabies virus, Bird, Disease, Toxoplasma gondii, Parasitism, Prevalence, Bartonella henselae, Face, Aerosol, Turtle, Campylobacteriosis, Dog, Toxoplasmosis, MRSA, Biting, Fungus, Hygiene, Cat, Thought, Mycobacterium, Giardiasis, Animal, Soil, Population, Psittacosis, Risk, Water, Pet, Rabies, Bacteria, Genetically modified bacteria, Birth, Death, Scratch, Virus, Meningitis, Pneumonia, Mouth, Saliva, Pet industry, Medical imaging, Vaccine, Trapping, Veterinary medicine, Animal husbandry, Pig, Poultry farming, Toy, Zoonosis

Pet ownership is at an all-time high, with a recent survey finding 69% of Australian households have at least one pet.

Key Points: 
  • Pet ownership is at an all-time high, with a recent survey finding 69% of Australian households have at least one pet.
  • We spend an estimated A$33 billion every year on caring for our fur babies.
  • But some, such as pregnant people and those with weakened immune systems, are at greater risk of getting sick from animals.

What diseases can pets carry?

    • Infectious diseases that move from animals to humans are called zoonotic diseases or zoonoses.
    • Zoonoses can be transmitted directly from pets to humans, such as through contact with saliva, bodily fluids and faeces, or indirectly, such as through contact with contaminated bedding, soil, food or water.
    • Both dogs and cats are also reservoirs for methicillin-resistant bacterium Staphylococcus aureus (MRSA), with close contact with pets identified as an important risk factor for zoonotic transmission.
    • Read more:
      Cats carry diseases that can be deadly to humans, and it's costing Australia $6 billion every year

Birds, turtles and fish can also transmit disease

    • Pet birds can occasionally transmit psittacosis, a bacterial infection which causes pneumonia.
    • Contact with pet turtles has been linked to Salmonella infections in humans, particularly in young children.
    • Even pet fish have been linked to a range of bacterial infections in humans, including vibriosis, mycobacteriosis and salmonellosis.
    • Close contact with animals – and some behaviours in particular – increase the risk of zoonotic transmission.

What should I do if I’m worried about catching a disease from my pet?


    There are a number of good hygiene and pet husbandry practices that can reduce your risk of becoming sick. These include:
    It is especially important for those who are at a higher risk of illness to take precautions to reduce their exposure to zoonotic pathogens. And if you’re thinking about getting a pet, ask your vet which type of animal would best suit your personal circumstances.

    Read more:
    One in three people are infected with _Toxoplasma_ parasite – and the clue could be in our eyes

Delve Bio Appoints Jim Stuart as Chief Commercial Officer

Retrieved on: 
Monday, August 28, 2023
Science, Other Science, Research, General Health, Health, Infectious Diseases, Genetics, Clinical Trials, Quest Diagnostics, University, Bio, Genomics, University of California, San Francisco, Infection, Jim Stuart, Personalized medicine, Genentech, Fungus, Cerebrospinal fluid, Dicarboxylic acid, Parasitism, Metagenomics, Delve, Bacteria, Anne, Encephalitis, Virus, Meningitis, Management, Pharmaceutical industry

Delve Bio, a pioneer in metagenomic next-generation sequencing (mNGS) for infectious diseases, today announced the appointment of Jim Stuart as chief commercial officer and Jay Wohlgemuth, M.D., to the board of directors.

Key Points: 
  • Delve Bio, a pioneer in metagenomic next-generation sequencing (mNGS) for infectious diseases, today announced the appointment of Jim Stuart as chief commercial officer and Jay Wohlgemuth, M.D., to the board of directors.
  • “We’re delighted to welcome Jim to our growing team,” said Brad Murray, co-founder and CEO of Delve Bio.
  • “His track record of driving commercial success in molecular diagnostics gives us full confidence in his ability to increase physician and patient access to our mNGS test.”
    Mr. Stuart joins Delve from Invitae, where he held positions of increasing responsibility, starting as the first employee on the commercial team and culminating as senior vice president, commercial.
  • Delve Bio emerged from stealth with $35 million in Series A financing in June.